| LDR | 01164nam a2200241 4500 | ||
| 001 | 010998713 | ||
| 003 | MiAaHDL | ||
| 005 | 20110502000000.0 | ||
| 006 | m d | ||
| 007 | cr bn ---auaua | ||
| 008 | 750404m19711974dcua b f00000 eng d | ||
| 035 | ⊔ | ⊔ | ‡asdr-chi31456 |
| 035 | ⊔ | ⊔ | ‡a(OCoLC)28788970 |
| 035 | ⊔ | ⊔ | ‡a(ICU)BID396663 |
| 040 | ⊔ | ⊔ | ‡aICU ‡cICU |
| 041 | 0 | ⊔ | ‡aeng |
| 110 | 1 | ⊔ | ‡aUnited States. ‡bCongress. ‡bSenate. ‡bSelect Committee on Small Business. ‡bSubcommittee on Monopoly |
| 245 | 1 | 0 | ‡aAdvertising of proprietary medicines. ‡bHearings, Ninety-first Congress, first session[-Ninety-second Congress, second session] on effect of promotion and advertising of over-the-counter drugs on competition, small business, and the health and welfare of the public. |
| 260 | 0 | ⊔ | ‡aWashington, ‡bU.S. Govt. Print. Off., ‡c1971-74. |
| 300 | ⊔ | ⊔ | ‡a4 v. (vi, 1672 p.) ‡billus. ‡c24 cm. |
| 504 | ⊔ | ⊔ | ‡aIncludes bibliographical references. |
| 538 | ⊔ | ⊔ | ‡aMode of access: Internet. |
| 650 | ⊔ | 0 | ‡aPatent medicines |
| 650 | ⊔ | 0 | ‡aAdvertising ‡xPharmaceutical industry. |
| CID | ⊔ | ⊔ | ‡a010998713 |
| DAT | 0 | ⊔ | ‡a19971004172400.0 ‡b20110502000000.0 |
| DAT | 1 | ⊔ | ‡a20120814082529.0 ‡b2024-08-12T17:34:29Z |
| DAT | 2 | ⊔ | ‡a2024-08-12T17:30:02Z |
| CAT | ⊔ | ⊔ | ‡aSDR-CHI ‡dUNKNOWN ‡lloader.pl-001-001 |
| FMT | ⊔ | ⊔ | ‡aBK |
| HOL | ⊔ | ⊔ | ‡0sdr-chi31456 ‡achi ‡bSDR ‡cCHI ‡pchi.44827749 ‡sCHI ‡zc.1 v.4 ‡131456 |
| 974 | ⊔ | ⊔ | ‡bCHI ‡cCHI ‡d20240812 ‡sgoogle ‡uchi.44827749 ‡zc.1 v.4 ‡y1974 ‡rpd ‡qbib ‡tUS fed doc |
| 974 | ⊔ | ⊔ | ‡bCHI ‡cCHI ‡d20240812 ‡sgoogle ‡uchi.37077202 ‡zc.1 v.3 ‡y1974 ‡rpd ‡qbib ‡tUS fed doc |
| 974 | ⊔ | ⊔ | ‡bCHI ‡cCHI ‡d20240811 ‡sgoogle ‡uchi.44827667 ‡zc.1 v.2 ‡y1974 ‡rpd ‡qbib ‡tUS fed doc |
| 974 | ⊔ | ⊔ | ‡bCHI ‡cCHI ‡d20240810 ‡sgoogle ‡uchi.44827814 ‡zc.1 v.1 ‡y1974 ‡rpd ‡qbib ‡tUS fed doc |